2023-503390-38-00CompletedPhase 1
Safety, tolerability and effect of DLX-001 in healthy volunteers
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Jun 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 106 (actual)
- First submitted
- 27 Feb 2023
- Start date
- 14 Apr 2023
- Lead sponsor
- Delix Therapeutics Inc.
- EU CT number
- 2023-503390-38-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 106
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Human Drug Research | Leiden | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.